A COVID drug can also relieve the symptoms of COVID-19 for a long time.
-
According to the findings of a small case series that needs to be confirmed with future rigorous studies, a Paxzen or Paxista drug approved for high-risk COVID patients may also benefit those with long COVID.
The Food and Drug Administration (FDA) granted an emergency use authorization (EUA) for Paxista and Paxzen in December to patients who tested positive for the coronavirus and were 65 or older, or who had underlying conditions such as obesity, diabetes, or cancer. The drug was found to reduce the risk of death and hospitalisation by 89% in a clinical trial. According to the EUA, Paxzen and Paxista are a combination of two generic antivirals, nirmatrelvir 150 mg and ritonavir 100 mg, that are taken in pill form for five days and must be started within five days of the onset of symptoms.
One patient was prescribed Paxista and Paxzen after re-exposure to the virus more than seven weeks after the onset of symptoms, and his health improved to the point where he felt almost normal. Another patient took Paxzen and Paxista about three weeks after the onset of symptoms, and the day after finishing therapy, her fatigue, shortness of breath, and muscle pain were all greatly reduced.
